Affinage

LDOC1

Protein LDOC1 · UniProt O95751

Length
146 aa
Mass
17.0 kDa
Annotated
2026-06-10
26 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LDOC1 is a nuclear leucine-zipper protein that functions as a tumor suppressor by restraining inflammatory and proliferative signaling and by shaping chromatin state (PMID:10403563, PMID:12712434, PMID:41484780). A core activity is inhibition of NF-κB transcription: LDOC1 blocks NF-κB reporter activity downstream of MEKK1, TNF-α, and PMA without affecting p53, AP-1, or CRE outputs, and its restoration lowers p50/p65 levels and suppresses tumor growth across oral, thyroid, and ependymoma models (PMID:12712434, PMID:23362108, PMID:31889386, PMID:39901723). LDOC1 also interacts with the nucleolar GTPase GNL3L, destabilizing it and reversing GNL3L-driven p65 activation (PMID:27764577). In parallel, LDOC1 nucleates a complex with phospho-JAK2 and the E3 ligase LNX1 that drives ubiquitin-dependent proteasomal degradation of pJAK2, thereby damping the IL-6/JAK2/STAT3 axis; loss of LDOC1 weakens LNX1-pJAK2 engagement and unleashes STAT3 activation (PMID:30634502, PMID:39901723). At the chromatin level, LDOC1 binds histone H2B, H2Bub1, PSMA1, and THAP12 and promotes proteasomal turnover of H2B/H2Bub1, limiting global H2Bub1 and controlling chromatin accessibility over metastasis genes; its loss enhances TGF-β-induced epithelial-mesenchymal plasticity (PMID:41484780). LDOC1 additionally promotes apoptosis through MZF-1-enhanced loss of mitochondrial membrane potential, and is negatively regulated by WAVE3, which binds its V-domain and relocalizes it from nucleus to cytoplasm (PMID:15670815, PMID:16272576). A genetic knockout establishes a developmental role in which LDOC1 controls placental trophoblast giant cell maturation and progesterone/lactogen output to time parturition (PMID:25468940). Across cancers LDOC1 is silenced epigenetically, by cigarette-smoke-induced DNMT-mediated promoter hypermethylation and by H3K27me3 chromatin compaction (PMID:26317789, PMID:39901723).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 1999 Medium

    Established the basic identity of LDOC1 as a nuclear protein with a leucine-zipper-like motif and an SH3-binding-like proline-rich region, framing it as a candidate signaling/regulatory protein.

    Evidence EGFP fusion localization, Northern blot and chromosomal mapping

    PMID:10403563

    Open questions at the time
    • No molecular partners or enzymatic activity defined
    • Functional role unknown at this stage
  2. 2003 Medium

    Answered what pathway LDOC1 acts on by showing it specifically inhibits NF-κB transcriptional activity, defining its first signaling role.

    Evidence NF-κB luciferase reporter assays with pathway-specificity controls and stable transfection

    PMID:12712434

    Open questions at the time
    • Did not identify the molecular step in NF-κB inhibited
    • Single lab, reporter-based
  3. 2005 Medium

    Connected LDOC1 to programmed cell death and identified its first physical partner, showing LDOC1 induces apoptosis via mitochondrial membrane potential loss enhanced by MZF-1.

    Evidence Apoptosis assays, mitochondrial membrane potential measurement, caspase-3 assay, Co-IP

    PMID:15670815

    Open questions at the time
    • Mechanism linking LDOC1 to mitochondrial depolarization unresolved
    • MZF-1 interaction not reciprocally mapped to domains
  4. 2005 Medium

    Identified WAVE3 as a negative regulator that controls LDOC1 localization, establishing that nuclear retention is required for LDOC1's pro-apoptotic function.

    Evidence Direct pulldown binding to the WAVE3 V-domain, fluorescence localization, apoptosis and p53 protein/mRNA analysis

    PMID:16272576

    Open questions at the time
    • How cytoplasmic relocalization inactivates LDOC1 not defined
    • p53 stabilization mechanism inferred, not directly shown
  5. 2013 Medium

    Demonstrated tumor-suppressive function in vivo by showing LDOC1 restoration suppresses NF-κB (p50/p65) and inhibits tumor growth in oral cancer.

    Evidence Ectopic expression, western blot for p50/p65, in vivo tumor model

    PMID:23362108

    Open questions at the time
    • Did not distinguish direct vs indirect NF-κB suppression
    • Co-effect with BEX1 not separated
  6. 2014 High

    Defined a physiological, non-cancer role by showing LDOC1 controls placental trophoblast giant cell maturation and parturition timing through progesterone/lactogen output.

    Evidence Knockout mouse with hormonal assays and placental histology

    PMID:25468940

    Open questions at the time
    • Molecular pathway linking LDOC1 to TGC differentiation unknown
    • Relationship to LDOC1's NF-κB role not addressed
  7. 2015 Medium

    Explained how LDOC1 becomes silenced in disease, showing cigarette smoke condensate drives DNMT1/DNMT3A-mediated promoter hypermethylation and that knockdown confers proliferative/clonogenic capacity.

    Evidence Methylation-specific PCR, CSC treatment, DNMT immunofluorescence, clonogenicity assay

    PMID:26317789

    Open questions at the time
    • Direct DNMT recruitment to LDOC1 locus not shown
    • Reversibility of silencing untested
  8. 2015 Medium

    Extended the NF-κB-suppressive tumor suppressor role to papillary thyroid cancer and linked it to restored TGF-β1 responsiveness.

    Evidence Lentiviral expression, NF-κB reporter, western blot panel, flow cytometry

    PMID:26637328

    Open questions at the time
    • Mechanistic link to TGF-β1 pathway not defined
  9. 2016 Medium

    Identified GNL3L as a physical partner whose destabilization underlies part of LDOC1's NF-κB suppression, connecting LDOC1 to a nucleolar GTPase.

    Evidence Reciprocal Co-IP, ectopic expression/knockdown, NF-κB reporter, proliferation assays

    PMID:27764577

    Open questions at the time
    • Mechanism of GNL3L destabilization unknown
    • Whether GNL3L is the dominant NF-κB route unclear
  10. 2017 Medium

    Linked LDOC1 to anti-metastatic activity, showing it lowers Wnt5a and reduces migration, invasion, and lung metastasis.

    Evidence Stable expression, transwell assays, metastasis gene qRT-PCR array, xenograft with micro-CT

    PMID:28240050

    Open questions at the time
    • Direct vs indirect Wnt5a regulation not established
  11. 2019 Medium

    Revealed a degradative mechanism by showing LDOC1 assembles with pJAK2 and the E3 ligase LNX1 to drive pJAK2 ubiquitination, suppressing STAT3 activation.

    Evidence Co-IP, confocal colocalization, in vivo xenograft with phosphorylation analysis

    PMID:30634502

    Open questions at the time
    • Ubiquitin linkage type and LDOC1's adaptor role not structurally defined
    • Direct vs scaffold function unclear
  12. 2019 Medium

    Placed LDOC1 in normal hematopoiesis as a target of AML exosomal miR-4532, whose loss activates JAK2/STAT3 and DKK1 to suppress hematopoiesis.

    Evidence miRNA target validation, gain/loss in CD34+ HSCs, exosome co-culture, CFU assays, western blot

    PMID:31842997

    Open questions at the time
    • Direct miR-4532/LDOC1 binding only implied
    • Mechanism overlapping with LNX1 axis not integrated
  13. 2019 Medium

    Showed LDOC1 also restrains Wnt/β-catenin signaling in colorectal cancer, broadening its anti-proliferative reach beyond NF-κB.

    Evidence Lentiviral expression, western blot, β-catenin immunofluorescence, Transwell/Matrigel, flow cytometry

    PMID:31002361

    Open questions at the time
    • Mechanism of β-catenin regulation undefined
  14. 2020 Medium

    Positioned LDOC1 upstream of the PI3K/Akt/GSK-3β axis controlling IL-1β during Candida albicans stimulation, extending its role to innate inflammatory output.

    Evidence Gain/loss-of-function, western blot for pAkt/pGSK-3β, PI3K/Akt inhibitors, GSK-3β S9A rescue

    PMID:33120999

    Open questions at the time
    • Direct molecular target of LDOC1 in this axis not identified
  15. 2020 Medium

    Confirmed that nuclear-to-cytoplasmic translocation inactivates LDOC1 in thyroid cancer and that its NF-κB suppression is functionally responsible for its anti-tumor phenotype via inhibitor epistasis.

    Evidence Subcellular fractionation/IF, lentiviral KD/OE, NF-κB reporter, NF-κB inhibitor epistasis

    PMID:31889386

    Open questions at the time
    • Trigger for mislocalization in tumors not defined
  16. 2024 Low

    Added an upstream regulatory layer in which LINC01270 sponges miR-326 to sustain LDOC1 and limit NF-κB activity.

    Evidence siRNA knockdown, luciferase reporter, RIP, synthetic RNA perturbation

    PMID:39682774

    Open questions at the time
    • LDOC1 is a downstream effector; direct mechanism on LDOC1 protein not addressed
    • Single lab, ceRNA-centric
  17. 2025 Medium

    Established an epigenetic mode of LDOC1 silencing in ependymoma (H3K27me3 compaction) and showed LDOC1 loss is required for tumor growth via NF-κB and IL-6.

    Evidence ChIP for H3K27me3, lentiviral restoration, NF-κB analysis, IL-6 ELISA, in vivo competition assay

    PMID:39901723

    Open questions at the time
    • Direct PRC2 recruitment to LDOC1 not shown
    • Link between NF-κB and IL-6 mechanistically incomplete
  18. 2026 High

    Defined LDOC1's chromatin mechanism, showing it interacts with H2B/H2Bub1, PSMA1, and THAP12 to drive proteasomal turnover of H2Bub1, controlling chromatin accessibility and EMT/metastasis programs.

    Evidence Co-IP, PLA, ChIP-seq, ATAC-seq, MNase digestion, transcriptomics, migration/adhesion assays

    PMID:41484780

    Open questions at the time
    • Whether H2Bub1 regulation is direct catalytic targeting or adaptor-mediated unresolved
    • Integration with NF-κB and JAK2 roles not established
  19. 2026 Low

    Reported a paradoxical bidirectional effect of LDOC1 on STAT1 transcription and phosphorylation, hinting at a role in pro-inflammatory signaling.

    Evidence Gain/loss-of-function, RT-qPCR, western blot for pSTAT1, target gene analysis

    PMID:41828328

    Open questions at the time
    • Paradoxical bidirectional result not mechanistically clarified
    • Single lab, single method set

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how LDOC1's distinct activities — NF-κB suppression, pJAK2/LNX1-mediated degradation, and H2Bub1 chromatin control — are mechanistically unified, and whether they reflect a single biochemical function or independent scaffolding roles.
  • No structural model of LDOC1 or its complexes
  • No defined catalytic activity
  • Relationship between developmental placental role and tumor-suppressor activity unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 3 GO:0060090 molecular adaptor activity 2 GO:0140096 catalytic activity, acting on a protein 2 GO:0042393 histone binding 1
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2 GO:0005694 chromosome 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3 R-HSA-5357801 Programmed Cell Death 2 R-HSA-1266738 Developmental Biology 1 R-HSA-4839726 Chromatin organization 1
Partners
GNL3LH2BJAK2LNX1MZF-1PSMA1THAP12WAVE3

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 LDOC1 encodes a nuclear protein with a leucine zipper-like motif at the N-terminal region and a proline-rich region similar to an SH3-binding domain; EGFP-LDOC1 fusion protein localizes to the nucleus. EGFP fusion protein localization assay, Northern blot, chromosomal mapping Cancer letters Medium 10403563
2003 LDOC1 inhibits NF-κB transcriptional activity; transient LDOC1 expression blocked NF-κB reporter activity driven by MEKK1, TNF-α, or PMA in a dose-dependent manner, without affecting p53, AP-1, or CRE-dependent reporter expression. NF-κB luciferase reporter assay, stable transfection, cell viability assay International journal of cancer Medium 12712434
2005 LDOC1 overexpression induces apoptosis via loss of mitochondrial membrane potential, leading to both caspase-3-dependent and -independent pathways; transcription factor MZF-1 physically interacts with LDOC1 and enhances its pro-apoptotic activity. Phosphatidylserine externalization assay, mitochondrial membrane potential measurement, caspase-3 activity assay, co-immunoprecipitation (MZF-1/LDOC1 interaction) FEBS letters Medium 15670815
2005 LDOC1 binds directly to the verprolin homology (V) domain of WAVE3; WAVE3 expression induces translocation of LDOC1 from the nucleus to the cytoplasm, inhibiting LDOC1-induced apoptosis; LDOC1-induced apoptosis is accompanied by increased p53 protein (not transcription), suggesting LDOC1 inhibits p53 degradation. Direct binding assay (pulldown), subcellular localization (fluorescence microscopy), apoptosis assay, p53 protein/mRNA analysis Journal of biochemistry Medium 16272576
2013 Restored expression of BEX1 and LDOC1 in OSCC cells suppresses NF-κB signaling, specifically decreasing p50 and p65 expression, and exerts growth inhibitory effects in vitro and in vivo. Ectopic expression, NF-κB pathway analysis (western blot for p50/p65), in vivo tumor model The Journal of pathology Medium 23362108
2014 Sirh7/Ldoc1 knockout mice show abnormal placental trophoblast giant cell (TGC) differentiation/maturation, leading to overproduction of placental progesterone (P4) and placental lactogen 1 (PL1), and delayed parturition with low pup weaning rate. Knockout mouse model, hormonal assays (P4, PL1 measurement), histological analysis of placenta Development (Cambridge, England) High 25468940
2016 LDOC1 physically interacts with GNL3L (a nucleolar GTPase); ectopic LDOC1 expression destabilizes endogenous GNL3L and down-modulates GNL3L-induced cell proliferation; GNL3L upregulates NF-κB-dependent transcriptional activity via p65, which is reversed by co-expression of LDOC1. Co-immunoprecipitation (protein-protein interaction assays), ectopic expression/knockdown, NF-κB reporter assay, cell proliferation assay Cell cycle (Georgetown, Tex.) Medium 27764577
2015 LDOC1 promoter is hypermethylated by cigarette smoke condensate (CSC) exposure via increased nuclear DNMT1 and DNMT3A accumulation; LDOC1 knockdown confers proliferative and clonogenic capacity on untransformed oral cells. Quantitative methylation-specific PCR, CSC treatment, DNMT immunofluorescence, loss-of-function knockdown with clonogenicity assay Oncotarget Medium 26317789
2015 LDOC1 overexpression in PTC cells suppresses proliferation and induces apoptosis by inhibiting NF-κB activation; LDOC1-overexpressing cells recover responsiveness to TGF-β1 antiproliferative signaling. Lentiviral ectopic expression, NF-κB luciferase reporter assay, western blot (p65, IκBα, c-Myc, Bax, Bcl-xL), flow cytometry Journal of experimental & clinical cancer research : CR Medium 26637328
2017 LDOC1 expression decreases Wnt5a levels in osteosarcoma cells and suppresses osteosarcoma cell migration and invasion in vitro; in a xenograft model, LDOC1 expression is associated with reduced lung metastasis. Lentiviral stable expression, transwell migration/invasion assay, qRT-PCR array for metastasis genes, xenograft model with micro-CT imaging Tumour biology Medium 28240050
2019 LDOC1 forms protein complexes with phospho-JAK2 (pJAK2) and E3 ubiquitin ligase LNX1, targeting pJAK2 for ubiquitin-dependent proteasomal degradation; LDOC1 deficiency reduces LNX1-pJAK2 interaction, leading to ineffective pJAK2 ubiquitination and consequent STAT3 activation. Co-immunoprecipitation, immunofluorescent confocal microscopy, in vivo xenograft with phosphorylation analysis Cancers Medium 30634502
2019 AML cell-derived exosomes deliver miR-4532 into hematopoietic stem cells (CD34+), where miR-4532 targets LDOC1 mRNA; loss of LDOC1 activates JAK2/STAT3 phosphorylation and increases DKK1, suppressing normal hematopoiesis; ectopic LDOC1 expression or JAK2 inhibition reverses these effects. miRNA target validation (luciferase/binding assay implied), gain- and loss-of-function in CD34+ HSCs, exosome co-culture, colony-forming unit assays, western blot for pJAK2/pSTAT3 Stem cell research & therapy Medium 31842997
2019 LDOC1 overexpression in colorectal cancer cells inhibits Wnt/β-catenin signaling, reducing nuclear β-catenin levels and suppressing proliferation, migration, and invasion while promoting apoptosis. Lentiviral ectopic expression, western blot, cellular immunofluorescence for β-catenin localization, Transwell and Matrigel assays, flow cytometry Oncology reports Medium 31002361
2020 LDOC1 deficiency increases Akt phosphorylation and subsequent inhibitory phosphorylation of GSK-3β (Ser9) upon Candida albicans stimulation, leading to increased IL-1β production; PI3K/Akt inhibitors or constitutively active GSK-3β (S9A mutant) reduce IL-1β in LDOC1-deficient cells, placing LDOC1 upstream of the PI3K/Akt/GSK-3β axis. Gain/loss-of-function (ectopic expression and knockdown), western blot for pAkt and pGSK-3β, pharmacological inhibitors (PI3K/Akt), active mutant GSK-3β (S9A) rescue experiment Cancers Medium 33120999
2020 LDOC1 is translocated from the nucleus to the cytoplasm in human thyroid cancer; LDOC1 ablation in PTC cells facilitates nuclear p65 expression and NF-κB activity; NF-κB inhibition reverses the effects of LDOC1 ablation on proliferation, apoptosis, migration, and invasion. Subcellular fractionation/immunofluorescence, lentiviral KD and OE, NF-κB luciferase reporter, NF-κB inhibitor epistasis experiment Cell biology international Medium 31889386
2024 LINC01270 acts as a competing endogenous RNA (ceRNA) for miR-326, maintaining LDOC1 expression; knockdown of LINC01270 downregulates LDOC1 and enhances NF-κB activity; luciferase reporter assay confirmed the LINC01270/miR-326/LDOC1 regulatory axis in NF-κB modulation. siRNA knockdown, luciferase reporter assay, RNA immunoprecipitation (RIP), synthetic RNA perturbation experiments Cells Low 39682774
2025 LDOC1 loss in PFA1 ependymoma results from H3K27me3-mediated chromatin compaction at the LDOC1 locus; restoration of LDOC1 reduces proliferation, NF-κB signaling, and IL-6 secretion; in vivo competition assay showed LDOC1-transduced tumor cells were outcompeted, indicating loss of LDOC1 is required for PFA tumor growth. ChIP (H3K27me3), lentiviral LDOC1 restoration, NF-κB pathway analysis, IL-6 ELISA, in vivo tumor competition model Neuro-oncology Medium 39901723
2026 LDOC1 physically interacts with histone H2B, H2Bub1, PSMA1, and THAP12; LDOC1 promotes proteasomal degradation of H2B and H2Bub1 via PSMA1, limiting global H2Bub1 levels; LDOC1 knockdown causes loss of chromatin-bound H2Bub1 and enhanced chromatin compaction partly through THAP12; the LDOC1-H2Bub1 axis regulates metastasis-related genes (cytoskeletal remodeling, cell adhesion, EMT); LDOC1 loss enhances TGF-β-induced epithelial-mesenchymal plasticity and promotes a hybrid E/M phenotype. Co-immunoprecipitation, proximity ligation assay, ChIP-seq, ATAC-seq, MNase digestion, transcriptomic profiling, immunofluorescence, flow cytometry, functional migration/adhesion assays Cell communication and signaling : CCS High 41484780
2026 LDOC1 regulates STAT1 transcription and phosphorylation in an unexpected bidirectional manner: both gain- and loss-of-function of LDOC1 upregulate STAT1 transcription, revealing a novel role for LDOC1 in modulating STAT1-dependent pro-inflammatory signaling. Gain- and loss-of-function (siRNA and overexpression), RT-qPCR, western blot for pSTAT1, downstream target gene analysis International journal of molecular sciences Low 41828328

Source papers

Stage 0 corpus · 26 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2013 Epigenetic regulation of the X-linked tumour suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. The Journal of pathology 79 23362108
2003 Leucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosis. International journal of cancer 65 12712434
1999 Identification of a novel gene, LDOC1, down-regulated in cancer cell lines. Cancer letters 64 10403563
2014 Sirh7/Ldoc1 knockout mice exhibit placental P4 overproduction and delayed parturition. Development (Cambridge, England) 56 25468940
2019 Acute myeloid leukemia cells secrete microRNA-4532-containing exosomes to mediate normal hematopoiesis in hematopoietic stem cells by activating the LDOC1-dependent STAT3 signaling pathway. Stem cell research & therapy 39 31842997
2005 LDOC1, a novel MZF-1-interacting protein, induces apoptosis. FEBS letters 38 15670815
2015 LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma. Journal of experimental & clinical cancer research : CR 35 26637328
2019 HAND2-AS1 inhibits invasion and metastasis of cervical cancer cells via microRNA-330-5p-mediated LDOC1. Cancer cell international 30 31889905
2016 Leucine Zipper Down-regulated in Cancer-1 (LDOC1) interacts with Guanine nucleotide binding protein-like 3-like (GNL3L) to modulate Nuclear Factor-kappa B (NF-κB) signaling during cell proliferation. Cell cycle (Georgetown, Tex.) 28 27764577
2019 Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer. Cancers 22 30634502
2017 NF-κB upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. Neuro-oncology 20 28510691
2015 LDOC1 silenced by cigarette exposure and involved in oral neoplastic transformation. Oncotarget 19 26317789
2013 Loss of LDOC1 expression by promoter methylation in cervical cancer cells. Cancer investigation 18 24125169
2005 WAVE3 functions as a negative regulator of LDOC1. Journal of biochemistry 18 16272576
2014 Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells. Archives of gynecology and obstetrics 13 24554348
2020 LDOC1 Suppresses Microbe-Induced Production of IL-1β in Human Normal and Cancerous Oral Cells through the PI3K/Akt/GSK-3β Axis. Cancers 12 33120999
2023 Calycosin inhibits gemcitabine-resistant lung cancer cells proliferation through modulation of the LDOC1/GNL3L/NFκB. The Chinese journal of physiology 6 37635478
2019 Salivary LDOC1 is a gender-difference biomarker of oral squamous cell carcinoma. PeerJ 6 30993049
2017 LDOC1 regulates Wnt5a expression and osteosarcoma cell metastasis and is correlated with the survival of osteosarcoma patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 6 28240050
2013 Overexpression of LDOC1 in human biliary epithelial cells inhibits apoptosis through NF-κB signaling. Journal of pediatric gastroenterology and nutrition 6 23942005
2019 Effects of LDOC1 on colorectal cancer cells via downregulation of the Wnt/β-catenin signaling pathway. Oncology reports 5 31002361
2024 LINC01270 Regulates the NF-κB-Mediated Pro-Inflammatory Response via the miR-326/LDOC1 Axis in THP-1 Cells. Cells 3 39682774
2020 LDOC1 is differentially expressed in thyroid cancer and display tumor-suppressive function in papillary thyroid carcinoma. Cell biology international 3 31889386
2026 LDOC1 connects histone H2B monoubiquitination to tumor cell plasticity in non-small cell lung cancer. Cell communication and signaling : CCS 0 41484780
2026 A Novel Role of the LINC01270/miR-326/LDOC1 Axis in Proinflammatory Response Regulation via STAT1 Modulation in THP-1 Cells. International journal of molecular sciences 0 41828328
2025 Loss of LDOC1 by chromatin compaction in mesenchymal tumor cells is required for PFA1 ependymoma growth. Neuro-oncology 0 39901723

Missed literature

Know a paper Affinage missed for LDOC1? Flag it for the maintainers and the community.

No submissions yet.